Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Precision OpticsPOCI 69 Debt-to-EBITDA is 97.25 as of Mar. 2026. GuruFocus rates POCI with a GF Score™ of 69/100 and a GF Value™ of $6.36 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 467 Medical Devices & Instruments companies, Precision Optics ranks worse than 214132.55% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Precision Optics's Debt-to-EBITDA or its related term are showing as below:
POCI'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -5.15 Med: -0.06 Max: 11.01
Current: -0.95
During the past 13 years, the highest Debt-to-EBITDA Ratio of Precision Optics was 11.01. The lowest was -5.15. And the median was -0.06.
POCI's Debt-to-EBITDA is ranked worse than 100% of 467
companies
in the Medical Devices & Instruments industry
Industry Median: 1.57
vs POCI: -0.95
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Precision Optics Debt-to-EBITDA Related Terms
Precision Optics Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Precision Optics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
POCI vs DXR, NEPH, MLSS: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Precision Optics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Precision Optics Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Precision Optics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Precision Optics's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Precision Optics (POCI) has a Debt-to-EBITDA of 97.25 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Precision Optics. According to the industry distribution chart, Precision Optics ranks #999999 out of 467 companies in the Medical Devices & Instruments industry.
Is Precision Optics' Debt-to-EBITDA too high?
Precision Optics' current Debt-to-EBITDA is 97.25. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.57. Precision Optics' value of 97.25 is 6094.3% above this industry median. Based on the distribution chart, Precision Optics ranks #999999 out of 467 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Precision Optics has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Precision Optics' Debt-to-EBITDA compare to DXR and NEPH?
According to the Medical Devices & Instruments industry distribution chart, Precision Optics ranks #999999 out of 467 companies for Debt-to-EBITDA. This places Precision Optics in the lower half of its industry. The industry median Debt-to-EBITDA is 1.57. Precision Optics' value of 97.25 is 6094.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.57, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Precision Optics's current Debt-to-EBITDA of 97.25 is 6094.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Precision Optics. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Precision Optics's current Debt-to-EBITDA is 97.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Precision Optics stock overvalued right now?
Based on GuruFocus' analysis, Precision Optics (POCI) is currently considered Possible Value Trap. The stock's GF Value™ is $6.36, compared to a current price of $4.30 — trading 32.4% below its estimated fair value. The current Debt-to-EBITDA is 97.25 and 6094.3% above the Medical Devices & Instruments industry median of 1.57. Precision Optics' overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Precision Optics (POCI), the current Debt-to-EBITDA is 97.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Precision Optics (POCI) Overvalued in 2026?
Based on GuruFocus' analysis, Precision Optics stock appears to be undervalued.
The current stock price of $4.30 is trading 32.4% below its estimated GF Value™ of $6.36.
GuruFocus considers Precision Optics to be Possible Value Trap.
Key valuation signals for POCI:
Debt-to-EBITDA: 97.25
GF Value™: $6.36 vs. price of $4.30 (32.4% below fair value)
Industry Position: 6094.3% above the Medical Devices & Instruments median (#999999 of 467)
No single metric tells the full story. See the POCI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Precision Optics Corp Inc is engaged in designing, developing, and manufacturing advanced optical instruments. It manufactures medical products such as endoscopes and endocouplers which incorporate various optical technologies for use in a variety of minimally invasive surgical and diagnostic procedures. The company also produces endoscopes for various applications as well as designs and manufactures custom optical medical devices to satisfy customers' specific requirements. In addition, the company manufactures and sells components and assemblies specially designed for industrial and military use. The company earns the majority of its revenue from the United States.
69GF Score
Get the complete analysis for POCI
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
POCI has been successfully added to your 
